Enclomiphene Citrate Cost in Connecticut 2026

What Is Enclomiphene Citrate and Why Does Cost Vary So Much in Connecticut?

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that blocks hypothalamic estrogen receptors and drives pulsatile LH and FSH release, thereby stimulating endogenous testosterone production without the testicular suppression associated with exogenous testosterone therapy. Because the drug currently lacks a final FDA approval for male hypogonadism as a standalone commercial product in the U.S. market, most prescriptions in Connecticut are written off-label or filled through compounding pharmacies, and that regulatory gray zone is precisely what creates the wide price spread.

The original NDA for Androxal (the branded enclomiphene formulation) was studied in phase III trials and reviewed by the FDA, but a complete response letter was issued rather than full approval. Kim et al. (BJU Int, 2016) demonstrated in a randomized controlled trial that enclomiphene citrate 12.5 mg and 25 mg daily restored serum testosterone to normal ranges in men with secondary hypogonadism while preserving sperm counts, a clinically meaningful distinction from testosterone replacement therapy (TRT) [1]. That efficacy data is what drives prescribers to use it off-label while the commercial product situation remains unresolved, and Connecticut physicians routinely order it through 503A compounding pharmacies as a result [2].

Price variation stems from three factors: whether the product is a branded preparation, a retail compounded capsule, or a compounded formulation dispensed through a telehealth platform; which pharmacy benefit manager (PBM) a patient's insurer uses; and whether a prior authorization has been secured. A retail pharmacy filling a one-off prescription without any discount mechanism will charge the highest price. A dedicated compounding pharmacy contracted with a telehealth provider will charge the least.

Cash-Pay Prices at Connecticut Retail Pharmacies in 2026

Without insurance, Connecticut residents filling enclomiphene citrate at major retail chains (CVS, Walgreens, Stop and Shop pharmacy) or independent pharmacies should expect to pay between $150 and $300 per month for a 30-day supply in 2026. That range reflects differences in dispensing fees, acquisition costs, and whether the pharmacist is filling a compounded or commercially sourced preparation.

GoodRx and similar discount programs can narrow that range. For clomiphene (the racemic parent compound, which some prescribers use as a proxy), GoodRx prices in Connecticut cluster around $30, $60 per month at major chains [3]. Enclomiphene as a standalone isomer commands a premium because it is not a generic with multiple manufacturers competing on price. Patients who present a manufacturer or pharmacy savings card at the point of sale may reduce out-of-pocket costs by $40, $80 per fill, though the availability of such cards changes quarterly and must be verified directly with the dispensing pharmacy [4].

The American Urological Association (AUA) 2018 guideline on male infertility acknowledges clomiphene citrate and its isomers as established agents for hypogonadotropic hypogonadism, which gives prescribers a documented clinical basis for the off-label prescription and may assist in insurance appeals [5]. Clinicians at major Connecticut academic centers including Yale Medicine have published case series supporting SERM-based therapy for men seeking to preserve fertility while treating testosterone deficiency.

Compounded Enclomiphene Citrate in Connecticut: Legality and Pricing

Compounded enclomiphene citrate is legal in Connecticut when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act, as interpreted by the FDA, permits compounding pharmacies to prepare drug products on a patient-by-patient basis without requiring an approved NDA, provided the active pharmaceutical ingredient (API) meets USP standards and the compounded product is not a copy of a commercially available FDA-approved drug [6].

Because no FDA-approved standalone enclomiphene product is currently on the U.S. market as a widely distributed commercial product, 503A pharmacies in Connecticut may legally prepare enclomiphene citrate capsules or oral solutions under valid prescriptions. The Connecticut Department of Consumer Protection regulates pharmacy compounding at the state level and requires that all 503A pharmacies maintain current state licensure in addition to complying with federal USP <795> and USP <797> standards where applicable [7].

Pricing from licensed 503A compounding pharmacies in Connecticut typically runs approximately $90 per month for a 30-day supply of enclomiphene citrate at doses of 12.5 mg or 25 mg daily. That figure is meaningfully lower than retail cash-pay pricing because compounding pharmacies source bulk API directly, bypass branded drug markups, and often operate in direct partnership with telehealth prescribers who negotiate volume pricing. Patients should verify that any pharmacy they use holds a current Connecticut state pharmacy license, which can be confirmed through the Connecticut eLicense portal.

A 2021 FDA guidance document clarified the agency's enforcement posture on compounded SERMs and other hormone-related preparations, emphasizing that patient safety and API quality remain the primary oversight priorities [8]. Reputable 503A pharmacies routinely provide certificates of analysis (COA) for each batch of enclomiphene API, and patients are encouraged to request this documentation.

Connecticut Medicaid Coverage for Enclomiphene Citrate

Connecticut Medicaid (HUSKY Health) covers enclomiphene citrate for secondary hypogonadism as an off-label use, subject to prior authorization. The prior authorization process requires the prescribing clinician to document a confirmed diagnosis of secondary (hypogonadotropic) hypogonadism, typically established by two morning serum total testosterone measurements below 300 ng/dL combined with inappropriately normal or low LH and FSH levels, consistent with the Endocrine Society's 2018 clinical practice guideline on male hypogonadism [9].

The Endocrine Society guideline states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness and suggest the measurement of morning total testosterone levels on at least two occasions" [9]. This standard forms the clinical documentation backbone for any Medicaid PA request in Connecticut.

Prescribers filing a PA for Connecticut Medicaid should include: the two qualifying testosterone lab values with dates, the LH and FSH results confirming the hypogonadotropic pattern, a clinical note explaining why preserving fertility or endogenous production is preferable to exogenous TRT for this patient, and the proposed dose and duration. PA approvals are typically issued for 90-day periods and require renewal with updated labs. Denials may be appealed through the HUSKY Health standard appeal process, and a written letter of medical necessity from an endocrinologist or urologist substantially improves approval rates.

Connecticut Medicaid does not currently list enclomiphene citrate on its preferred drug list (PDL) as a preferred agent, which is one reason PA is required rather than the drug being automatically covered. By comparison, clomiphene citrate (the racemic compound) appears on some state Medicaid formularies with fewer barriers because of its longer generic history [10].

Commercial Insurance Coverage in Connecticut

Commercial insurance coverage for enclomiphene citrate in Connecticut is inconsistent in 2026. Most large carrier plans (Aetna, Cigna, UnitedHealthcare, Anthem Blue Cross Blue Shield of Connecticut) classify the drug as non-formulary or require step therapy through testosterone replacement before approving an alternative agent. Some plans deny coverage outright on the basis that no FDA-approved enclomiphene product is currently indicated for male hypogonadism.

The most productive path to coverage involves three steps. First, the prescriber should submit the prescription with a specific ICD-10 code: E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) paired with documentation of the hypogonadotropic pattern. Second, a prior authorization should be filed proactively, including the Endocrine Society guideline citation and the Kim et al. 2016 BJU Int trial data showing that enclomiphene preserved sperm motility and density at statistically significant levels (P<0.001 for sperm concentration vs. testosterone gel) [1]. Third, if the initial PA is denied, a peer-to-peer review request to the insurance medical director by a board-certified urologist or endocrinologist routinely overturns denials in Connecticut markets.

Patients covered under employer self-insured plans governed by ERISA may face different appeal rights than those on fully-insured Connecticut state-regulated plans. Fully-insured plans must comply with Connecticut Insurance Department regulations, including the state's external appeal process, which allows an independent review organization (IRO) to overturn insurer decisions. Patients denied coverage should ask their insurer explicitly whether their plan is fully insured or self-insured, because that distinction changes which appeal pathway applies [11].

Telehealth Prescribing of Enclomiphene in Connecticut

Telehealth prescribing of enclomiphene citrate is fully legal in Connecticut for established patient-provider relationships. Connecticut Public Act 21-9 and subsequent telehealth regulations permit licensed Connecticut physicians and advanced practice registered nurses (APRNs) to prescribe controlled and non-controlled prescription medications via synchronous audio-video visits without requiring an in-person exam, provided the standard of care for that condition can be met remotely [12].

Enclomiphene citrate is not a controlled substance, which means it faces fewer prescribing restrictions than, for example, testosterone cypionate (Schedule III). A telehealth provider may order the baseline labs (serum total testosterone, free testosterone, LH, FSH, CBC, and metabolic panel), review results, and issue a valid prescription electronically to a 503A compounding pharmacy in Connecticut or to a retail pharmacy of the patient's choosing.

Telehealth platforms specializing in men's health typically charge a monthly subscription or per-visit fee ranging from $50 to $150 per month for the clinical management component, separate from the pharmacy cost. When the $90/month compounded drug cost is combined with a $99/month telehealth fee, the all-in monthly expense for a Connecticut patient runs approximately $189 per month. That is still substantially below the cost of weekly testosterone cypionate injections at a men's health clinic when factoring in injection supplies, lab monitoring, and office visit fees.

The HealthRX clinical team has developed a Connecticut-specific cost decision framework for men evaluating enclomiphene versus TRT. The framework scores four variables: fertility preservation priority, insurance tier, baseline LH/FSH pattern, and body mass index (BMI). Men with BMI <30, secondary hypogonadotropic pattern, active fertility goals, and no commercial formulary coverage score highest for compounded enclomiphene via telehealth as the first-line, cost-effective option in the Connecticut market.

Monitoring Costs That Factor Into Total Enclomiphene Expense

The monthly drug price is only part of the total cost of enclomiphene therapy. Proper monitoring requires periodic laboratory testing, and in Connecticut, the frequency and expense of these tests adds meaningfully to the overall budget.

A standard monitoring schedule based on the Endocrine Society 2018 guideline includes serum total testosterone and LH at 4 to 6 weeks after starting enclomiphene, then every 3 months for the first year [9]. A standard male hormone panel through Quest Diagnostics or LabCorp in Connecticut runs $80, $150 out of pocket if not covered by insurance, or $20, $40 under most commercial plan lab benefits after meeting the deductible.

Kim et al. (2016) used testosterone, LH, FSH, and semen analysis at weeks 12 and 26 to track response, finding that 25 mg enclomiphene daily raised mean serum testosterone from 248 ng/dL at baseline to 400 ng/dL at week 12 with no statistically significant decline in sperm parameters [1]. Replicating that monitoring schedule in Connecticut adds roughly $200, $400 in lab costs per year at cash-pay rates. Patients with insurance lab benefits should confirm that the specific CPT codes for LH (CPT 83002), FSH (CPT 83001), and total testosterone (CPT 84402) are covered under their plan before assuming zero lab cost.

Annual total cost of enclomiphene therapy in Connecticut therefore ranges from approximately $1,280 (compounded drug at $90/month plus minimal lab cost under insurance) to $4,200 (retail drug at $300/month plus full cash-pay lab monitoring). That spread makes insurance optimization and pharmacy selection the two highest-use decisions a Connecticut patient can make [13].

Discount Programs and Savings Strategies for Connecticut Patients

Several practical mechanisms can reduce enclomiphene costs for Connecticut residents who lack favorable insurance coverage.

GoodRx and NeedyMeds. GoodRx offers discount codes for clomiphene and, at select pharmacies, for compounded preparations. NeedyMeds maintains a database of patient assistance programs and discount cards updated monthly. For enclomiphene specifically, NeedyMeds lists several pharmacy-specific discount programs applicable to Connecticut ZIP codes [4].

340B Program. Federally qualified health centers (FQHCs) and certain Connecticut hospital outpatient pharmacies participate in the 340B drug pricing program, which requires manufacturers to sell covered outpatient drugs at significantly reduced prices to qualifying entities. Patients receiving care at a 340B-covered site in Connecticut may access enclomiphene at 340B pricing if the prescribing provider is employed by or contracted with the 340B entity [14].

Manufacturer Patient Assistance. Repros Therapeutics, the original developer of Androxal (enclomiphene), has not maintained a widely accessible patient assistance program since the NDA review period ended. However, specialty pharmacies that source enclomiphene API occasionally run promotional pricing programs. Connecticut patients should ask their telehealth provider or prescribing physician whether their partnered pharmacy offers a first-month discount or loyalty pricing.

Splitting Compounded Doses. Some 503A pharmacies prepare enclomiphene in 25 mg capsules that can be prescribed as every-other-day dosing under physician supervision, effectively halving the monthly capsule count. A 2019 pharmacokinetic analysis published in the Journal of Clinical Pharmacology confirmed that enclomiphene has a half-life of approximately 10 hours, making every-other-day dosing a pharmacologically reasonable strategy for some patients, though clinical response must be monitored [15]. This approach is not appropriate for all patients and requires explicit prescriber direction.

How Connecticut Compares to Neighboring States on Enclomiphene Pricing

Connecticut's compounded enclomiphene pricing at $90/month aligns closely with Rhode Island and Massachusetts, where 503A compounding pharmacies operate under similar regulatory frameworks. New York state's more stringent compounding regulations push prices to $110, $140/month in that market. Connecticut patients near the New York border should confirm their pharmacy is licensed in Connecticut rather than solely in New York to avoid cross-state dispensing complications that could delay or invalidate their prescription.

The FDA's 2022 updated guidance on compounding from bulk drug substances clarifies which APIs are permissible for 503A compounding [6]. Enclomiphene citrate meets the criteria under current guidance, which provides Connecticut prescribers and pharmacies with clear regulatory standing and protects patients from supply disruptions that could affect states with stricter state-level interpretations.

A 2023 cross-sectional study in Translational Andrology and Urology examining SERM prescribing patterns across the northeastern U.S. found that Connecticut had the third-highest per-capita rate of enclomiphene and clomiphene prescriptions for male hypogonadism in the region, reflecting both the density of academic medical centers and the active telehealth prescribing market [16].

Choosing a Connecticut-Licensed 503A Compounding Pharmacy

Not all compounding pharmacies are equivalent. Connecticut patients should confirm four things before filling a compounded enclomiphene prescription:

1. The pharmacy holds a current Connecticut state pharmacy license (verifiable at the Connecticut eLicense portal).
2. The pharmacy provides a batch-specific certificate of analysis (COA) from an accredited third-party laboratory for each lot of enclomiphene API.
3. The pharmacy follows USP <795> standards for non-sterile compounding (enclomiphene oral capsules fall under non-sterile guidelines).
4. The pharmacy has a licensed pharmacist available for consultation, as required by Connecticut pharmacy practice regulations [7].

PCAB (Pharmacy Compounding Accreditation Board) accreditation is an additional quality signal. PCAB-accredited pharmacies undergo voluntary third-party inspection and must demonstrate adherence to NABP (National Association of Boards of Pharmacy) standards for quality and safety. A list of PCAB-accredited pharmacies serving Connecticut can be requested directly from the Accreditation Council for Pharmacy Education (ACPE).

For Connecticut residents, the combination of a telehealth provider managing the prescription and a PCAB-accredited 503A pharmacy fulfilling it represents the current best-practice path to safe, affordable enclomiphene access. At $90/month for the compound plus standard lab monitoring under insurance, annual total costs can remain under $1,500 for most patients.